Τίτλος:
Pharmacotherapeutic advances for recurrent urinary tract infections in women
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction: Treatment of recurrent Urinary tract infections (UTIs) has become challenging because of the dramatic increase in the rates of recurrent infection andof multidrug-resistant (MDR) infections. Areas covered: The authors review recurrent UTIs(rUTI) management in women. Expert opinion: Continuous or post-coital prophylaxis with low-dose antimicrobials or intermittent self-treatment has all been demonstrated to be effective in managing rUTIs in women. Intravaginal estrogen therapy, shows potential toward preventing rUTI. Oral vaccine Uro-Vaxom seems to reduce the number of UTIs. There is evidence that other therapies (e.g. cranberry, Methenamine hippurate, oral D-mannose) may decrease the number of symptomatic UTIs. The treatment of CRE-UTIs is focused on a colistin backbone. Carbapenems are considered first-line agents for UTIs caused by ESBL, but their use is associated with increased MDR. The usage of non-carbapenem for the treatment of ESBL UTIs is necessary. Cefepime, Piperacillin-Tazobactam, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam are justified options. Oral therapy with Pivmecillinam, Fosfomycin, and Nitrofurantoin can be used against uncomplicated UTIs due to ESBL infection. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Moussa, M.
Abou Chakra, M.
Dellis, A.
Moussa, Y.
Papatsoris, A.
Περιοδικό:
Expert Opinion on Pharmacotherapy
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
antiinfective agent; avibactam, ceftazidime drug combination; azabicyclo derivative; ceftazidime; ceftolozane, tazobactam drug combination; cephalosporin derivative; fosfomycin; tazobactam, beverage; chemistry; cranberry; drug combination; female; human; microbiology; recurrent disease; secondary prevention; urinary tract infection, Anti-Bacterial Agents; Azabicyclo Compounds; Beverages; Ceftazidime; Cephalosporins; Drug Combinations; Female; Fosfomycin; Humans; Recurrence; Secondary Prevention; Tazobactam; Urinary Tract Infections; Vaccinium macrocarpon
DOI:
10.1080/14656566.2020.1795128
